- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117960
Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD
April 7, 2015 updated by: Tehran University of Medical Sciences
Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With Coronary Artery Disease
The aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of BMP-4, YKL40, HSP70, HSP27 in patients with cardiovascular disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of BMP-4, YKL40, HSP70, HSP27 in patients with cardiovascular disease.
In this randomized, double-blind clinical trial, placebo-controlled, single-center, and phase two trials, 42men aged 45-65 years with Coronary Artery Disease are enrolled in the study from Tehran Heart Center.
After signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days will be taken from the participants at the beginning and the end of the study,.
Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo.
The supplement group, will receive 4 g/day omega 3 fatty acid for 8 weeks and the placebo group will also receive placebo (containing 4 g of edible paraffin) (similar in terms of color, shape and size).
Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity.
Blood samples will be collected after 8-12 hours fasting and anthropometric variables, biochemical parameters and physical activity before and after the trial will be measured.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Tehran University of Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- CVD patients 45- 65 years old, patients with ≥ 50% stenosis in at least one coronary angiogram demonstrated, body mass index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention, willingness to participation,
Exclusion Criteria:
- people who have used omega 3 supplements in last 3 months, having chronic renal disease , GI disease, hepatobiliary diseases, hematological disorders, hypo- or hyperthyroidism, Smokers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: CVD, Placebo
patients with cardiovascular disease who receive 4 cap of placebo/day
|
4 cap 1 g Placebo(paraffin) per day for 2 months
|
|
Active Comparator: CVD, Omega-3
patients with Cardiovascular disease who receive 4g/d omega-3
|
4 cap 1 g Omega-3 per day for 2 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum Heat Shock Protein 70(HSP70)
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum Ox-LDL
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
|
Serum BMP4 (Bone Morphogenic Protein4)
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
|
Serum Heat Shock Protein 27(HSP27)
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
|
Serum YKL40
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
|
Serum hsCRP
Time Frame: Change frome baseline at 2 months
|
Change frome baseline at 2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Mahmoud Jalali, Ph.D, Department of Nutrition & Biochemistry, School of Public Health, Tehran University of Medical Sciences (TUMS)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
October 1, 2013
Study Registration Dates
First Submitted
April 16, 2014
First Submitted That Met QC Criteria
April 16, 2014
First Posted (Estimate)
April 21, 2014
Study Record Updates
Last Update Posted (Estimate)
April 8, 2015
Last Update Submitted That Met QC Criteria
April 7, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2486
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingCardiovascular Disease (CVD) | Gender Incongruence | Cardiovascular (CV) Risk | Cardiovascular Health Status | Cardiovascular Disease Prevention | Cardiovascular Disease Acute | Cardiovascular Disease Risk FactorItaly
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
University College DublinBeacon Hospital, IrelandRecruitingCoronary Artery Disease (CAD) | Cardiovascular Diseases (CVD) | Cardiovascular Disease Prevention | Cardiovascular Disease Risk FactorIreland
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Istituti Clinici Scientifici Maugeri SpAA.R.C.A Associazioni Regionali Cardiologi AmbulatorialiRecruiting
-
AmgenRecruitingCardiovascular DiseaseItaly, Germany, United States, China, Japan, Spain, Denmark, Australia, France, Canada, Netherlands
-
University of ReadingBiotechnology and Biological Sciences Research Council; Royal Berkshire NHS...Not yet recruiting
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States